<DOC>
	<DOCNO>NCT00924508</DOCNO>
	<brief_summary>The primary objective clinical study determine whether occlusion triamcinolone 0.1 % cream ( TAC ) hydrogel patch improve efficacy treat eczema . A secondary objective determine whether eczema improves occlusion hydrogel patch alone , without TAC .</brief_summary>
	<brief_title>Hydrogel Patch Treatment Eczema</brief_title>
	<detailed_description>This 6-week , open label , bilaterally-controlled single center study involve 30 subject age 13 old eczema . The primary objective clinical study determine whether occlusion triamcinolone 0.1 % cream ( TAC ) use treat eczema hydrogel patch improve efficacy . A secondary objective determine whether eczema improves occlusion hydrogel patch alone . All subject 3 target lesion similar severity follow throughout study . Patients apply hydrogel patch alone first lesion , TAC 0.1 % cream second lesion , TAC 0.1 % cream occlude hydrogel patch third lesion . All treatment twice day maximum 4 week lesion clear . The modified Eczema Area Severity Index ( EASI ) score use evaluate lesion .</detailed_description>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>1 . Subject sign informed consent form Health Insurance Portability Accountability Act ( HIPAA ) authorization form ; 2 . Male female subject least 12 year age ; subject 18 year age need parental official guardian consent . 3 . A diagnosis eczema least three lesion large 7 7 cm either trunk , arm , leg would serve target lesion . The lesion must wide enough apart overlap hydrogel patch . All three lesion must least 5 12 point modify EASI scale . Each three lesion must great 1 point difference modify EASI score . ( If subject identify specific eczema lesion pruritic , recalcitrant and/or tend initiate itchscratch cycle , lesion preferentially select target lesion . ) 4 . Any additional diagnosis must , investigator 's opinion , preclude subject safely participate study interfere evaluation subject 's eczema ; 5 . Subject able completely discontinue use medication therapy ( study medication ) relief eczema target area treat ; 6 . Subject able completely discontinue use systemic medication therapy ( e.g . oral medication , phototherapy , herbal remedy , acupuncture ) relief eczema ; 7 . Subject must reliable mentally competent complete study measurement ; 8 . Subject able understand agree comply study requirement , attend study visit , comply restriction study . 1 . Subjects exclusively hand , face , foot , and/or groin dermatitis 2 . Known hypersensitivity component test medication ; 3 . Pigmentation , extensive scarring , pigment lesion affected area would interfere evaluation efficacy parameter ; 4 . Clinically infected eczema baseline . 5 . Any evidence atrophy area select treatment topical corticosteroid ; 6 . Subjects require medication ( topical systemic ) may affect course disease study period ( e.g . oral corticosteroid , immunosuppressant , antibiotic , sedate antihistamine ) . Inhaled steroid permit . 7 . Topical therapy ( nonprescription emollient ) potential target lesion within one week start study treatment ; 8 . Systemic therapy , phototherapy , systemic investigational therapy eczema within 30 day prior study entry ; 9 . Subject consider unreliable medication compliance adherence schedule appointment determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>eczema</keyword>
	<keyword>least 3 patch eczema</keyword>
</DOC>